PharmaNest provides high-resolution, single-fiber phenotypic quantification of fibrosis from digital images of conventional stained slides
for clinical and pre-clinical studies
FibroNest analysis of a liver biopsy of a patient with MASH
Why Single-Fiber, High-Resolution Analysis Matters?
Fibrosis is not a uniform process—it’s a complex reorganization of collagen fibers that reflects the balance between injury and repair. Traditional histological scoring and bulk collagen measurements often overlook the micro-architectural details that drive disease progression or regression.
Single-fiber, high-resolution analysis captures these nuances. By quantifying each collagen fiber’s geometry, thickness, orientation, and connectivity, it reveals patterns of tissue remodeling that correspond to biological mechanisms and treatment effects. This approach enables:
Sensitivity: Detects subtle, early changes before they are visible by conventional scoring.
Objectivity: Provides continuous, reproducible measurements independent of reader bias.
Spatial Insight: Maps fibrotic micro-environments across tissue layers and regions.
Translational Power: Links preclinical fiber phenotypes to clinical outcomes and therapeutic response.
Seamless Integration into Conventional Digital Pathology Workflows
The FibroNest™ platform is designed to integrate effortlessly into existing digital pathology workflows, minimizing disruption while maximizing analytical value. It operates directly on standard whole-slide images (WSI)—the same files already produced in routine pathology or CRO workflows—without requiring additional staining, scanning, or image preparation.
Through its interoperable architecture, FibroNest connects easily with most image management systems (IMS) and laboratory information systems (LIS), accepting common slide formats (e.g., SVS, NDPI, MRXS) and exporting structured quantitative outputs in familiar formats (CSV, XLSX, JSON). This enables researchers, pathologists, and data scientists to plug FibroNest directly into their analysis pipelines, visualization dashboards, or statistical environments.
Key Benefits of Seamless Integration:
No Workflow Disruption: Uses standard H&E or trichrome slides—no new protocols needed.
Rapid Deployment: Cloud- or server-based setup compatible with existing infrastructure.
Traceability & Compliance: All analyses are audit-trailed and align with regulatory standards for clinical and preclinical studies.
Enhanced Collaboration: Results can be shared across pathology teams and biostatistics groups in real time.
Scalable Data Generation: Converts entire slide archives into structured, quantitative fibrosis datasets ready for AI, biomarker, or outcome modeling.
In essence, FibroNest extends the power of traditional digital pathology—turning histology slides into quantitative, reproducible, and translationally relevant fibrosis data without changing how pathologists already work.
Translational Capabilities Across the Drug Discovery and Development Pipeline
The FibroNest™ platform bridges preclinical discovery and clinical translation through quantitative, single-fiber analysis and spatial profiling of fibrosis across species and therapeutic modalities.
Using a consistent analytical framework—from animal models to human biopsies—it enables tracing of biological mechanisms, quantifying therapeutic effects, and validating histological biomarkers throughout development.
With its companion module FibroMAP™, FibroNest identifies reproducible spatial phenotypes, or fibrotypes, that capture distinct tissue remodeling patterns linked to disease stage or treatment response. Together, they provide a unified translational bridge connecting digital histology, biology, and clinical outcomes.
Key Translational Strengths:
Cross-Species Continuity: Uses consistent digital biomarkers in preclinical and clinical settings, supporting back-translation and mechanism-of-action validation.
Mechanistic Insight: Identifies distinct fibrosis phenotypes and microarchitectural changes that correspond to drug response or resistance.
Regulatory Alignment: Provides quantitative, auditable metrics suitable for inclusion in biomarker qualification, IND submissions, and endpoint harmonization.
Therapeutic Breadth: Deployed across multiple disease areas—MASH, IBD (UC/CD), PSC, EoE, cardiac and pulmonary fibrosis, oncology, and regenerative medicine—to assess both disease progression and tissue repair.
Predictive Power: Links histological remodeling patterns to functional and clinical outcomes, accelerating translational decision-making.